Efficacy and safety of TAK-085 compared with eicosapentaenoic acid in Japanese subjects with hypertriglyceridemia undergoing lifestyle modification: The omega-3 fatty acids randomized double-blind (ORD) study

Journal of Clinical Lipidology

Volumn 7, Issue 3, 2013, Pages 199-207

  Tatsuno, Ichiro ^a   Saito, Yasushi ^b   Kudou, Kentarou ^c   Ootake, Jun ^c  

^a TOHO UNIVERSITY SAKURA MEDICAL CENTER   (Japan)

^b CHIBA UNIVERSITY   (Japan)

^c TAKEDA PHARMACEUTICAL COMPANY LIMITED   (Japan)

Author keywords

Docosahexaenoic acid; Dyslipidemia; Eicosapentaenoic acid; Hypertriglyceridemia; Omega 3 fatty acid; TAK 085

Indexed keywords

APOLIPOPROTEIN B; CREATINE KINASE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; ICOSAPENTAENOIC ACID; LOW DENSITY LIPOPROTEIN CHOLESTEROL; OMEGA 3 ACID ETHYL ESTER; VERY LOW DENSITY LIPOPROTEIN CHOLESTEROL;

ARTICLE; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DIARRHEA; DOUBLE BLIND PROCEDURE; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; HUMAN; HYPERTRIGLYCERIDEMIA; LIFESTYLE MODIFICATION; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MYELOFIBROSIS; PATIENT COMPLIANCE; PHARYNGITIS; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RHINOPHARYNGITIS; TREATMENT OUTCOME; UPPER RESPIRATORY TRACT INFECTION;

ASIAN CONTINENTAL ANCESTRY GROUP; DOCOSAHEXAENOIC ACIDS; DOUBLE-BLIND METHOD; EICOSAPENTAENOIC ACID; FATTY ACIDS, OMEGA-3; FEMALE; HUMANS; HYPERTRIGLYCERIDEMIA; LIFE STYLE; MALE; TRIGLYCERIDES;

EID: 84878567066     PISSN: 19332874     EISSN: 18764789     Source Type: Journal    
DOI: 10.1016/j.jacl.2013.01.006     Document Type: Article

References (25)

1. G. Assmann, H. Schulte, and A. von Eckardstein Hypertriglyceridemia and elevated lipoprotein (a) are risk factors for major coronary events in middle-aged men Am J Cardiol 77 1996 1179 1184 (Pubitemid 26186958)
2. J.E. Hokanson, and M.A. Austin Plasma triglyceride levels is a risk factor for cardiovascular disease independent of high-density lipoprotein cholesterol levels: a meta-analysis of population-based prospective studies J Cardiovasc Risk 3 1996 213 219 (Pubitemid 26266496)
3. B.G. Nordestgaard, M. Benn, P. Schnohr, and A. Tybjaerg-Hansen Nonfasting triglycerides and risk of myocardial infarction, ischemic heart disease, and death in men and women JAMA 298 2007 299 308 (Pubitemid 47080484)
4. National Cholesterol Education Program (NCEP), Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Final Report Circulation 106 2002 3143 3421
5. P.M. Kris-Etherton, W.S. Harris, and L.J. Appel Fish consumption, fish oil, omega-3 fatty acids, and cardiovascular disease Circulation 106 2002 2747 2757 (Pubitemid 35364932)
6. T. Teramoto, J. Sasaki, H. Ueshima Committee for Epidemiology and Clinical Management of Atherosclerosis Goals of dyslipidemia management- executive summary of Japan Atherosclerosis Society (JAS) guideline for diagnosis and prevention of atherosclerotic cardiovascular diseases for Japanese J Atheroscler Thromb 14 2007 209 212
7. M. Yokoyama, and H. Origasa Effects of eicosapentaenoic acid on cardiovascular events in Japanese patients with hypercholesterolemia: rationale, design, and baseline characteristics of the Japan EPA Lipid Intervention Study (JELIS) Am Heart J 146 2003 613 620 (Pubitemid 37281704)
8. M.L. Burr, A.M. Fehily, and J.F. Gilbert Effects of changes in fat, fish, and fibre intakes on death and myocardial reinfarction: diet and reinfarction trial (DART) Lancet 334 1989 757 761 (Pubitemid 19234807)
9. GISSI-Prevenzione Investigators Dietary supplementation with n-3polyunsaturated fatty acids with vitamin E after myocardial infarction: results of the GISSI-Prevenzione trial Lancet 354 1999 447 455
10. R. Marchioli, F. Barzi, E. Bomba GISSI-Prevenzione Investigators Early protection against sudden death by n-3 polyunsaturated fatty acids after myocardial infarction Circulation 105 2002 1897 1903
11. C. Wang, W.S. Harris, and M. Chung n-3 fatty acids from fish or fish-oil supplements, but not α-linoleic acid, benefit cardiovascular disease outcomes in primary- and secondary - prevention studies: a systematic review Am J Clin Nutr 84 2006 5 17 (Pubitemid 44699166)
12. H. Iso, M. Kobayashi, J. Ishihara JPHC Study Group Intake of fish and n3 fatty acids and risk of coronary heart disease among Japanese: the Japan Public Health Center-Based (JPHC) Study Cohort I Circulation 113 2006 195 202
13. L. Hooper, R.L. Thompson, and R.A. Harrison Omega 3 fatty acids for prevention and treatment of cardiovascular disease (review) Cochrane Database Syst Rev 4 2004 CD003177
14. K.C. Maki, M.R. Dicklin, A. Lawless, and M.S. Reeves Omega-3 fatty acids for the treatment of elevated triglycerides Clin Lipidol 4 2009 425 437
15. J.M. McKenney, and D. Sica Prescription omega-3 fatty acids for the treatment of hyperetriglyceridemia Am J Health Syst Pharm 64 2007 595 605 (Pubitemid 46481860)
16. W.S. Harris, and D. Bulchandani Why do omega-3 fatty acids lower serum triglycerides? Curr Opin Lipidol 17 2006 387 393 (Pubitemid 44079475)
17. W.S. Harris, M. Miller, A.P. Tighe, M.H. Davidson, and E.J. Schaefer Omega-3 fatty acids and coronary heart disease risk: clinical and mechanistic perspectives Atherosclerosis 197 2008 12 24
18. H.E. Bays, A.P. Tighe, R. Sadovsky, and M.H. Davidson Prescription omega-3 fatty acids and their lipid effects: physiologic mechanisms of action and clinical implications Expert Rev Cardiovasc Ther 6 2008 391 409
19. W.S. Harris, H.N. Ginsberg, and N. Arunakul Safety and efficacy of Omacor in severe hypertiglyceridemia J Cardiovasc Risk 4 1997 385 391 (Pubitemid 28078682)
20. L. Borthwick The effects of omega-3 ethyl ester concentrate on blood lipid concentrations in patients with hyperlipidaemia Clin Drug Invest 15 1998 397 404 (Pubitemid 28243007)
21. H.E. Bays, K.C. Maki, and J. Mckenney Long-term up to 24-month efficacy and safety of concomitant prescription omega-3-acid ethyl esters and simvastatin in hypertriglyceridemic patients Curr Med Res Opin 26 2010 907 915
22. M.H. Davidson, K.C. Maki, H. Bays, R. Carter, and C.M. Ballantyne Effects of prescription omega-3-acid ethyl esters on lipoprotein particle concentrations, apolipoproteins AI and CIII, and lipoprotein-associated phospholipase A(2) mass in statin-treated subjects with hypertriglyceridemia J Clin Lipidol 3 2009 332 340
23. J.G. Robinson, and N.J. Stone Antiatherosclerotic and antithrombotic effects of omega-3 fatty acids Am J Cardiol 4 Suppl 1 2006 39 49 (Pubitemid 44226453)
24. C.M. Ballantyne, H.E. Bays, and J.J. Kastelein Efficacy and safety of eicosapentaenoic acid ethyl ester (AMR101) therapy in statin-treated patients with persistent high triglycerides (from the ANCHOR study) Am J Cardiol 110 2012 984 992
25. H.E. Bays, C.M. Ballantyne, J.J. Kastelein, J.L. Issacsohn, R.A. Braeckman, and P.N. Soni Eicosapentaenoic acid ethyl ester (AMR 101) therapy in patients with very high triglyceride levels (from the Muticenter, plAcebo-controlled, Randomized, double-bliNd, 12-week study with an open-label Extension [MARINE] Trial) Am J Cardiol 108 2011 682 690